Company’s 36-month beta value is 0.97.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EFTR is 3.22M, and currently, short sellers hold a 10.72% ratio of that floaft. The average trading volume of EFTR on April 19, 2024 was 377.51K shares.
EFTR) stock’s latest price update
eFFECTOR Therapeutics Inc (NASDAQ: EFTR)’s stock price has gone decline by -5.82 in comparison to its previous close of 1.89, however, the company has experienced a -20.36% decrease in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-09 that SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET.
EFTR’s Market Performance
EFTR’s stock has fallen by -20.36% in the past week, with a monthly drop of -85.49% and a quarterly drop of -83.21%. The volatility ratio for the week is 11.55% while the volatility levels for the last 30 days are 14.35% for eFFECTOR Therapeutics Inc The simple moving average for the past 20 days is -78.10% for EFTR’s stock, with a -87.00% simple moving average for the past 200 days.
Analysts’ Opinion of EFTR
Many brokerage firms have already submitted their reports for EFTR stocks, with Stifel repeating the rating for EFTR by listing it as a “Hold.” The predicted price for EFTR in the upcoming period, according to Stifel is $6.20 based on the research report published on January 25, 2022 of the previous year 2022.
Stifel, on the other hand, stated in their research note that they expect to see EFTR reach a price target of $20. The rating they have provided for EFTR stocks is “Buy” according to the report published on November 09th, 2021.
Credit Suisse gave a rating of “Outperform” to EFTR, setting the target price at $20 in the report published on October 12th of the previous year.
EFTR Trading at -83.22% from the 50-Day Moving Average
After a stumble in the market that brought EFTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.19% of loss for the given period.
Volatility was left at 14.35%, however, over the last 30 days, the volatility rate increased by 11.55%, as shares sank -86.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -82.79% lower at present.
During the last 5 trading sessions, EFTR fell by -20.36%, which changed the moving average for the period of 200-days by -91.32% in comparison to the 20-day moving average, which settled at $7.5757. In addition, eFFECTOR Therapeutics Inc saw -84.77% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EFTR starting from SR ONE CAPITAL MANAGEMENT, LLC, who sale 609,163 shares at the price of $0.61 back on Nov 27 ’23. After this action, SR ONE CAPITAL MANAGEMENT, LLC now owns 1,821,415 shares of eFFECTOR Therapeutics Inc, valued at $369,457 using the latest closing price.
Stock Fundamentals for EFTR
The total capital return value is set at 6.49. Equity return is now at value -946.56, with -144.33 for asset returns.
Based on eFFECTOR Therapeutics Inc (EFTR), the company’s capital structure generated 1.42 points at debt to capital in total, while cash flow to debt ratio is standing at -1.52. The debt to equity ratio resting at -3.36. The interest coverage ratio of the stock is -24.02.
Currently, EBITDA for the company is -33.73 million with net debt to EBITDA at -0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.77.
Conclusion
In a nutshell, eFFECTOR Therapeutics Inc (EFTR) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
